MX2024013537A - Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina - Google Patents
Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolinaInfo
- Publication number
- MX2024013537A MX2024013537A MX2024013537A MX2024013537A MX2024013537A MX 2024013537 A MX2024013537 A MX 2024013537A MX 2024013537 A MX2024013537 A MX 2024013537A MX 2024013537 A MX2024013537 A MX 2024013537A MX 2024013537 A MX2024013537 A MX 2024013537A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- bcl
- degraders
- heterobifunctional
- tetrahydroisoquinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339253P | 2022-05-06 | 2022-05-06 | |
| US202263398783P | 2022-08-17 | 2022-08-17 | |
| US202263429862P | 2022-12-02 | 2022-12-02 | |
| US202363449756P | 2023-03-03 | 2023-03-03 | |
| US202363454545P | 2023-03-24 | 2023-03-24 | |
| US202363457997P | 2023-04-07 | 2023-04-07 | |
| PCT/US2023/021010 WO2023215482A1 (en) | 2022-05-06 | 2023-05-04 | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013537A true MX2024013537A (es) | 2024-12-06 |
Family
ID=86688472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013537A MX2024013537A (es) | 2022-05-06 | 2024-10-31 | Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240238423A9 (enExample) |
| EP (1) | EP4519259A1 (enExample) |
| JP (1) | JP2025517642A (enExample) |
| KR (1) | KR20250008772A (enExample) |
| CN (1) | CN119343345A (enExample) |
| AU (1) | AU2023264018A1 (enExample) |
| CA (1) | CA3251489A1 (enExample) |
| CL (1) | CL2024003362A1 (enExample) |
| IL (1) | IL316465A (enExample) |
| MX (1) | MX2024013537A (enExample) |
| PE (1) | PE20250007A1 (enExample) |
| TW (1) | TW202400589A (enExample) |
| WO (1) | WO2023215482A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202527930A (zh) * | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| TW202535872A (zh) * | 2023-11-07 | 2025-09-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101575A1 (en) * | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| WO2025130875A1 (zh) * | 2023-12-18 | 2025-06-26 | 南京瑞初医药有限公司 | 氮杂环化合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| CN113660937A (zh) | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN112707900B (zh) | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| US12441722B2 (en) | 2020-01-15 | 2025-10-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| US20230167105A1 (en) | 2020-04-28 | 2023-06-01 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| US20250197387A1 (en) | 2021-09-17 | 2025-06-19 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
| EP4431511A4 (en) * | 2021-11-09 | 2025-10-15 | Hangzhou Glubio Pharmaceutical Co Ltd | WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE |
-
2023
- 2023-05-04 EP EP23728483.1A patent/EP4519259A1/en active Pending
- 2023-05-04 AU AU2023264018A patent/AU2023264018A1/en active Pending
- 2023-05-04 US US18/143,454 patent/US20240238423A9/en active Pending
- 2023-05-04 CA CA3251489A patent/CA3251489A1/en active Pending
- 2023-05-04 JP JP2024565273A patent/JP2025517642A/ja active Pending
- 2023-05-04 CN CN202380046254.4A patent/CN119343345A/zh active Pending
- 2023-05-04 KR KR1020247040564A patent/KR20250008772A/ko active Pending
- 2023-05-04 IL IL316465A patent/IL316465A/en unknown
- 2023-05-04 WO PCT/US2023/021010 patent/WO2023215482A1/en not_active Ceased
- 2023-05-04 TW TW112116645A patent/TW202400589A/zh unknown
- 2023-05-04 PE PE2024002436A patent/PE20250007A1/es unknown
-
2024
- 2024-10-31 MX MX2024013537A patent/MX2024013537A/es unknown
- 2024-11-04 CL CL2024003362A patent/CL2024003362A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003362A1 (es) | 2025-03-07 |
| EP4519259A1 (en) | 2025-03-12 |
| TW202400589A (zh) | 2024-01-01 |
| PE20250007A1 (es) | 2025-01-07 |
| WO2023215482A1 (en) | 2023-11-09 |
| US20240238423A9 (en) | 2024-07-18 |
| JP2025517642A (ja) | 2025-06-10 |
| AU2023264018A1 (en) | 2024-11-07 |
| CA3251489A1 (en) | 2023-11-09 |
| US20230390404A1 (en) | 2023-12-07 |
| CN119343345A (zh) | 2025-01-21 |
| IL316465A (en) | 2024-12-01 |
| KR20250008772A (ko) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013537A (es) | Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina | |
| MX2024015265A (es) | Degradadores heterobifuncionales de bcl6 de 1,8-naftiridin-2-ona | |
| MX2024015036A (es) | Degradadores bifuncionales de bcl6 de quinolona triciclica | |
| MA31419B1 (fr) | Derives de pyridine | |
| YU3902A (sh) | Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva | |
| DE69732490D1 (en) | Monozyclische n-heterozyclische thiosäure derivate als antikoagulans | |
| PT863891E (pt) | (metilsulfonil)fenil-2-(5h)furanonas como inibidores de cox-2 | |
| DE69924135D1 (de) | Heterozyklische kalium-kanal inhibitoren | |
| GR81766B (enExample) | ||
| AP2000001889A0 (en) | Substituted ozoazaheterocyclyl factor Xa inhibitors. | |
| AP9901478A0 (en) | Compounds for the treatment of ischemia. | |
| AP2001002224A0 (en) | Benzoheterocycles and their use as MEK inhibitors. | |
| YU64100A (sh) | Postupak za sintetizovanje cox-2 inhibitora | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| ATE384701T1 (de) | Isochinolinone als kalium-kanal-inhibitoren | |
| MXPA02011425A (es) | Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa. | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| CO2026003544A2 (es) | Degradadores bifuncionales de quinolona tricíclica bcl6 | |
| MXPA03000161A (es) | Compuestos novedosos los cuales tienen actividad antiinflamatoria, proceso para su preparacion y composiciones farmaceuticas que las contienen. | |
| YU75101A (sh) | Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa | |
| MX2024015240A (es) | Degradadores bifuncionales de bcl6 de quinolona | |
| MX2024013312A (es) | Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina | |
| MX2025008428A (es) | Derivados de piperidina como inhibidores de mettl3 | |
| ES2182035T3 (es) | Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa. | |
| DE69702182D1 (de) | Alkylierte styrole als prodrugs zu cox-2-inhibitoren |